IMP321: Phase IIb started

Prima began the European Phase IIb AIPAC trial of subcutaneous IMP321 on days 2 and 16 of each 4-week cycle

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE